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T
ype 2 diabetes is a progressive dis-
easeinwhichtherisksofmyocardial
infarction, stroke, microvascular
events, and mortality are all strongly as-
sociated with hyperglycemia (1). The dis-
easecourseisprimarilycharacterizedbya
decline in -cell function and worsening
of insulin resistance. The process is man-
ifested clinically by deteriorations in mul-
tiple parameters, including A1C, fasting
plasma glucose (FPG), and postprandial
glucose levels.
In this review, we will evaluate our
current understanding of the role played
bydeteriorating-cellfunctionandother
abnormalitieslinkedwiththeprogression
of type 2 diabetes. An improved under-
standing of these abnormalities may pro-
vide the scientiﬁc groundwork for novel
therapies that may help achieve and
maintain good glycemic control.
CHARACTERISTICS OF
DISEASE PROGRESSION
Progression from pre-diabetes to
overt diabetes
Because glucose is a continuous variable,
the use of thresholds to make a diagnosis
is somewhat arbitrary. The term “pre-
diabetes” has become well established
and implies a risk of progression to overt
diabetes. However, although such pro-
gression is well studied in prevention tri-
als, little is known about the rate of
progression and the characteristics of
such progression in the population at
large.Table1summarizessomeofthefac-
torsassociatedwithsuchprogression.Ni-
chols et al. (2) studied the progression of
pre-diabetes to overt disease and ob-
served that 8.1% of subjects whose initial
abnormal fasting glucose was 100–109
mg/dland24.3%ofsubjectswhoseinitial
abnormal fasting glucose was 110–125
mg/dl developed diabetes over an average
of 29.0 months (1.34 and 5.56% peryear,
respectively). A steeper rate of increasing
fastingglucose;higherBMI,bloodpressure,
and triglycerides; and lower HDL choles-
terol predicted diabetes development.
The Baltimore Longitudinal Study of
Aging (3) concluded that although phe-
notypicdifferencesinratesofprogression
are partly a function of diagnostic thresh-
olds, fasting and postchallenge hypergly-
cemia may represent phenotypes with
distinct natural histories in the evolution
of type 2 diabetes.
Does hyperglycemia evolve from nor-
moglycemia gradually over time or as a
step increase? Ferrannini et al. (4) mea-
sured plasma glucose and insulin levels
duringoralglucosetestingatbaselineand
after 3 and 7 years of follow-up. In sub-
jects with normal glucose tolerance on all
three occasions (nonconverters), FPG in-
creased only slightly over 7 years. In con-
trast,conversiontobothimpairedglucose
tolerance (IGT) and diabetes among nor-
mal glucose tolerance subjects was
marked by a large step-up in FPG. Con-
verters had higher baseline BMI and fast-
ing plasma insulin concentrations than
nonconverters; however, no consistent
change in either parameter had occurred
beforeconversion.Incontrast,changesin
2-h post-glucose insulin levels between
time of conversion and preceding mea-
surement were inversely related to the
changes in FPG. Thus, within a 3-year
time frame, the onset of diabetes is often
rapid rather than gradual and is in part
explained by a fall in glucose-stimulated
insulin response.
The acute insulin response
The natural course of -cell function sug-
gests that the acute insulin response plays
a major role in determining glucose toler-
ance status over time. Among Pima Indi-
ans, over a mean of 5.1 years, progressors
(from normal glucose tolerance to IGT
and then diabetes) differed signiﬁcantly
from nonprogressors in their acute insu-
lin response. Acute insulin response de-
creased by 27% during the transition
from normal to impaired glucose toler-
ance and by 51% during the transition
fromimpairedglucosetolerancetodiabe-
tes, and in nonprogressors, it actually in-
creased by 30% (5).
Festa et al. assessed longitudinal
changes in -cell function over 5 years
(Fig. 1). Again, the main determinant of
glucose tolerance status during follow-up
was the change in acute insulin response.
Normalglucosetolerancewasmaintained
by a compensatory increase in insulin se-
cretion, whereas failure to increase insu-
lin secretion led to impaired glucose
tolerance, and a decrease in insulin secre-
tion led to overt diabetes (6).
Thus,theprogressivedecreasein-cell
insulin secretion, particularly the ﬁrst-
phase insulin secretion that occurs acutely
after an increase in glycemia, is likely the
most critical functional -cell defect in the
development of type 2 diabetes.
Progression to medication
The next step in progression could be de-
ﬁned by the need for medication. Pani et
al. (7) examined predictors of diabetes
progression (A1C 7% or initiation of
hypoglycemic agent) over 1 year in 705
patientswhohadA1C7%andwerenot
on glucose-lowering medications at base-
line. In the 200 patients who progressed,
baseline A1C, younger age, and weight
gain were independent predictors of pro-
gression. Each decade of increasing age
reduced the risk of progression by 15%.
Each 1-lb increase in weight was associ-
atedwitha2%increasedoddsofprogres-
sion. Likelihood of medication initiation
among progressors decreased by 40%
(P  0.02) with every decade of age and
decreased by 2.3% with each 1 mg/dl de-
crease in LDL level from baseline after ad-
justing for race, sex, and weight change.
Thus,amonguntreatedpatientswithA1C
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weight gain were more likely to have dia-
betesprogressionandshouldbethefocus
of aggressive diabetes management. A
limitation of this study is that physician
bias may have precluded or delayed initi-
ation of treatment in older patients. This
study provides indirect evidence that the
pathogenesisoftype2diabetesinsubjects
who develop diabetes at a younger age is
different from that of older subjects and
younger patients should be managed
moreaggressivelywithearlierinitiationof
medications.Conversely,theremaybean
identiﬁable subset of older patients with
stable weight who may be followed with-
out initiating pharmacological therapy.
Loss of glycemic control on
medication
Major clinical trials provide evidence of
the increasing loss of glycemic control
over time in type 2 diabetes. The U.K.
Prospective Diabetes Study (UKPDS)
showedthattherapywithmetformin,sul-
fonylurea, or insulin substantially low-
ered A1C and FPG compared with
conventional therapy, but over 11 years,
increased signiﬁcantly (8,9). A similar
pattern with sulfonylureas was observed
more recently in A Diabetes Outcome
Progression Trial (ADOPT), over a me-
dian of 4.0 years (10).
Matthews et al. (11) assessed the pre-
dictors of sulfonylurea failure in the UK-
PDS. By 6 years, 44% had required
additional therapy. Of those randomized
to glibenclamide, 48% required addi-
tional therapy by 6 years, compared with
40% of those allocated to chlorpropam-
ide. Not surprisingly, a higher initial fast-
ing glucose predicted greater need for
additional therapy.
In the initial 3 years, nonobese sub-
jects (BMI 30 kg/m
2) were more likely
to require additional therapy than obese
patients (BMI 30 kg/m
2). Modeled
-cell function showed that those with
lower function were more likely to fail
(P0.0001).Thus,sulfonylureasfailasa
therapeutic agent at rates that are depen-
dent both on the phenotype at presenta-
tion and perhaps on the agent used
initially. Higher failure rates were found
in individuals with higher glucose con-
centrations, those who were younger,
those with lower -cell reserve, and those
randomized to glibenclamide compared
with chlorpropamide.
-Cell function decline: the major
cause of disease progression
A hallmark of type 2 diabetes is a decline
in -cell function, which begins as early
as 12 years before diagnosis and contin-
uesthroughoutthediseaseprocess.Using
the homeostasis model assessment
(HOMA) to quantify -cell function, the
UKPDS demonstrated that, -cell func-
tion continued to deteriorate in associa-
tion with progressively increasing
hyperglycemia despite treatment (12).
As -cell function continues to de-
cline, monotherapy failure (in ADOPT
deﬁned as FPG 180 mg/dl) is almost
inevitable. In ADOPT, monotherapy with
metformin, rosiglitazone, and glyburide
all failed over time, albeit with differences
in the rates of decline. At 5 years, the cu-
mulative incidence of monotherapy fail-
urewas15%withrosiglitazone,21%with
metformin, and 34% with glyburide. After
initial improvement in glycemia, glyburide
had the greatest annual increases in A1C
andFPG(0.24and5.6mg/dl,respectively),
followed by metformin (0.14 and 2.7 mg/
dl,respectively)androsiglitazone(0.07and
0.7 mg/dl, respectively) (10).
Attempts to quantify -cell failure in-
clude the work of Wallace and Matthews,
who plotted A1C against time to derive a
coefﬁcient of failure for subjects with di-
abetes on constant monotherapy. In the
UKPDS, the mean coefﬁcient of failure
with chlorpropamide and glibenclamide
was 0.34 A1C%/year and 0.50 HbA1%/
year, respectively (13). The coefﬁcient of
failure has several advantages in assessing
-cell failure rates: it uses rates of change,
rather than absolute values; it can use
other measures of glycemia besides A1C;
and it allows comparisons between trials
and thus meta-analyses.
Because A1C will increase by 1%
every 2 years even with most therapies
(Fig. 2), patients with diabetes require re-
peated and vigorous intervention. Failure
to implement such interventions, owing
to “clinical inertia” or patient noncompli-
ance,resultsinworseningglucosecontrol
and perpetuates a vicious circle of hyper-
glycemia and glucose toxicity. Impor-
tantly, failure of -cell function in the late
stages of the disease is further com-
poundedbythecomplicationsofdiabetes
and by the likelihood of signiﬁcant co-
morbidities in elderly patients.
Natural history of obesity:
progressive weight gain
Weight gain is another common concern
as type 2 diabetes progresses. In UKPDS
Figure 1—Changes of insulin sensitivity (Si) and acute insulin response to glucose (AIR) from
baseline(arrowbase)tofollow-up(arrowtop)inpopulationsstratiﬁedbybaselineandfollow-up
glucose tolerance status (6). DM, diabetes; NGT, normal glucose tolerance.
Table 1—Factors associated with progres-
sion of pre-diabetes to diabetes
Elevated FPG and increase in FPG
High BMI
Weight gain
Younger age
High plasma insulin
Decreased insulin response to glucose
Dyslipidemia
Hypertension
Poor -cell function
Choice of treatment
Progression of type 2 diabetes
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enced the greatest weight gain over 10
years, followed by sulfonylurea treat-
ment; weight gain was lowest and similar
in conventional (diet) and metformin
treatment groups (8). In the Treat-to-
Target trial, weight gain at the end of 6
months was 3.0 and 2.8 kg with bedtime
glargine and NPH insulin, respectively
(14). In ADOPT, weight gain with rosigli-
tazone was almost 5 kg over 5 years. In
contrast, with glyburide, weight gain of
1.6 kg occurred in the ﬁrst year, but sta-
bilized thereafter, and weight decreased
by 3 kg in the metformin group (10).
Thecontributionofweightgaintodisease
progression is unclear. On the other
hand, weight loss is associated with im-
proved -cell function and a decreased
need for treatment.
PATHOPHYSIOLOGY OF
-CELL FAILURE— Pancreatic -cells
normally respond to insulin resistance by
increasing their output of insulin to meet
the needs of tissues. Development of type
2 diabetes essentially stems from a failure
ofthe-celltoadequatelycompensatefor
insulin resistance. The -cell dysfunction
progressesovertimeandiswelladvanced
by the time a person’s plasma glucose
levelisinthediabeticrangeandcontinues
to worsen after diabetes develops (12).
Many obese individuals, who tend to
haveinsulinresistance,progresstodiabe-
tes. Yet some do not: their -cells con-
tinue to function adequately and they are
able to maintain glucose homeostasis and
compensate for increasing insulin resis-
tance with increasing insulin secretion.
Genetic predisposition to -cell
failure
Data strongly support a genetic predispo-
sitionto-cellfailure(15).Ageneticsub-
type of the disease characterized by
diagnosis at 25 years of age, -cell dys-
function, an autosomal dominant mode
of inheritance, and heterozygous muta-
tions in -cell transcription factors has
been identiﬁed as a common cause of ear-
ly-onsettype2diabetes(16).Multiplege-
netic mutations have been identiﬁed, and
in some affected individuals, a genetic
cause for their disease is recognized (17).
However, in most patients in clinical
practice, it is impossible to identify a ge-
netic abnormality clinically and environ-
mental factors predominate.
Mechanisms responsible for the
decline in insulin secretion
Normal -cell adaptation to insulin resis-
tancecanoccurthroughincreasedinsulin
secretion from each -cell and/or an in-
crease in the -cell mass. Some individu-
als have a reduced insulin secretion or
reduced -cell mass but normal glucose
levels; they have sufﬁcient insulin sensi-
tivity to ensure adequate insulin secre-
tion. In insulin-resistant subjects or
subjects with type 2 diabetes, there is in-
adequate insulin secretion from each
-celloraninadequate-cellmassforthe
levels of prevailing insulin sensitivity (5).
Whenbloodglucoseiselevated,insu-
lin secretion is stimulated and glucagon
secretion is suppressed. Conversely,
when blood glucose is decreased, insulin
secretion should be suppressed and glu-
cagon secretion stimulated. All of these
actions are highly glucose dependent and
critical to maintain normal glycemia in
the face of varying insulin needs. They
also provide the classic response to a
meal. Although the failing -cell loses its
ability to respond to glucose, not all re-
sponses are diminished. Insulin secre-
tion, e.g., in response to amino acid
stimulation or through stimulation with
other hormones such as glucagon-like
peptide 1 (GLP-1), is preserved.
-Cellsmaintaintheirresponsiveness
in the face of insulin resistance through
increased insulin secretion in response to
meals as well as through a chronic re-
sponse by increasing -cell mass (18).
Normal-weight and obese individuals
maintain a normal and similar 24-h glu-
cose response to meals. However, the
groups differ in their mean insulin secre-
tion,whichissigniﬁcantlyhigherinobese
subjects than in their normal-weight
counterparts. In addition, insulin secre-
tion in obese subjects fails to return to
baseline between meals (19).
Two acquired defects have been im-
plicated with regard to impaired glucose
secretion: glucotoxicity, whereby -cells
become sensitized to the presence of glu-
cose, and lipotoxicity, whereby accumu-
lated fatty acids and their metabolic
products deleteriously affect -cells. In
glucotoxicity, chronic hyperglycemia de-
pletes insulin secretory granules from
-cells, lessening the amount of insulin
availabletobereleasedinresponsetonew
glucose stimuli. Lowering glucose levels
permitsregranulationof-cellsandabet-
teracuteinsulinresponsefollows.Inlipo-
toxicity, prolonged increases in free fatty
acid levels adversely affect the conversion
of proinsulin to insulin and eventually af-
fect insulin secretion. Fatty inﬁltration of
pancreatic islets may also contribute to
-celldysfunction,andpancreaticfatcor-
relates negatively with -cell function
(20).Butoncediabetesoccurs,factorsad-
ditionaltopancreaticfat(perhapsglucose
toxicity) account for further -cell func-
tion decline. The concepts of gluco- and
lipotoxicity remain hypotheses; the exact
mechanisms responsible for impaired
-cellfunctionhaveyettobeconclusively
proved. This concept is being tested fur-
therinclinicaltrialssuchasORIGIN(21),
where insulin will be used early to elimi-
nateglucotoxicityanddeterminewhether
earlyandmaintainednormoglycemiawill
decrease disease progression. The con-
cept of remission in diabetes by elimina-
tion of glucotoxicity has actually been
tested in a few small studies (22).
In addition to glucose and lipid dep-
osition in the pancreas, another local fac-
tor may be the accumulation of amyloid,
which has long been associated with the
development and progression of type 2
diabetes (23).
Thus, in type 2 adipogenic diabetes,
excessive carbohydrate and fat intake
causes hyperinsulinemia in association
Figure 2—Illustration of coefﬁcient of -cell failure over time in relation to A1C (from UKPDS)
(13).
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tion,adiposetissuegrowth,andincreased
free fatty acid levels in genetically suscep-
tible individuals. Together with episodes
of postprandial hyperglycemia, elevated
free fatty acid levels cause muscle and
liver insulin resistance and increase he-
patic glucose production. The same stim-
uli also facilitate -cell compensation by
promoting insulin secretion and biosyn-
thesis as well as -cell growth. In late
stages, however, the progressive rise in
insulin resistance, combined with alter-
ations in -cell gene expression and sig-
nalinginducedbyrisinglevelsoffreefatty
acids, cause -cell failure. Overt diabetes
occursasaresultofthis-celldecompen-
sation, with altered insulin secretion and
apoptosisaspossiblecontributingfactors.
-Cell mass deﬁcits
Although -cell function is paramount,
decreasing -cell mass is an important
factor in progression of type 2 diabetes.
-Cellmassisincreasedbyneogenesis,as
well as replication and hypertrophy. In
individuals who do not have diabetes,
these activities are counterbalanced by
apoptosisandnecrosis,therebymaintain-
ing a balance in -cell mass. In individu-
als who are obese or insulin resistant, the
number of islets and -cells, in the pres-
ence of increased insulin demand, in-
crease with some degree of hypertrophy
(18).Severalfactorsandmechanismsreg-
ulate -cell mass, and only in a minority
of diabetic patients does one single etio-
logical factor underlie the failure of the
-cell. The various factors regulating
mass are summarized in Fig. 3 (24). In
animal models of insulin resistance, there
is both replication of existing -cells and
neogenesisfromductalprecursorcells.In
the Zucker diabetic fatty rat model, Pick
et al. (25) determined -cell mass and
replicationrates.Innondiabeticbutobese
rats, the size of the islets increased. In
contrast,obesediabeticratsshowedslight
decreases in islets and in the amount of
insulin stained, whereas glucagon was ei-
ther maintained or increased (25). The
-cell replication rate was signiﬁcantly
greater in Zucker diabetic fatty rats than
ineitherleancontrolorobesenondiabetic
animals.Inaddition,increasedapoptosis,
rather than decreased neogenesis, is the
major factor responsible for reduction in
-cell mass (25).
In human autopsy pancreatic tissue
(18), subjects with impaired fasting glu-
cose and type 2 diabetes had a relatively
reduced -cell mass, whether they were
lean or obese. Obese subjects without di-
abetes had an 50% increase in relative
-cell volume. Obese subjects with im-
paired fasting glucose or type 2 diabetes
had 40 and 63% deﬁcits, respectively, in
relative-cellvolumethanobesesubjects
without diabetes. These in vivo ﬁndings
suggest that a decreased number of
-cells,ratherthanadecreasedvolumeof
individual cells, causes -cell volume de-
crease. Subjects with impaired fasting
glucose also had decreased relative -cell
volume, suggesting that this is an early
process and mechanistically important in
the development of type 2 diabetes (18).
In another recent autopsy study, there
was a signiﬁcant curvilinear relation be-
tween -cell volume and fasting blood
glucose level, and -cell deﬁciency was
associated with a steep increase in blood
glucose with further decrement in -cell
mass (26).
Abnormalities in the pancreatic islets
may also contribute to deﬁcits in -cell
mass with type 2 diabetes. Insulin secre-
tion from islets of organ donors who had
diabetes was signiﬁcantly less than that of
control subjects, and islet yield decreased
as disease duration lengthened (27).
Imaging studies substantiate that the
pancreas declines in size as type 2 diabe-
tesprogresses.Morethan20yearsago,we
usedultrasoundtoshowsomedecreasein
early type 2 disease and a signiﬁcant de-
crease in later-stage disease with declin-
ing -cell function and mass (28). Using
computerized tomography, Goda et al.
demonstratedthatpancreaticvolumeand
pancreatic volume index were greatest in
the healthy group and lowest in type 1
diabetes, although subjects with type 2
disease did not differ signiﬁcantly com-
pared with control subjects (29).
Does the amount of pancreatic mass
matter or can the residual mass take on
theload?Anintriguinginsightisprovided
by a study on donors of pancreatic tissue.
Hemipancreatectomy for the purpose of
organdonationhasbeenassociatedwitha
25% risk of developing abnormal glucose
tolerance or diabetes in the year after sur-
gery (30), and 43% of healthy humans
who underwent hemipancreatectomy
have impaired fasting glucose, impaired
glucose tolerance, or diabetes on follow-
up. These ﬁndings are compatible with
Figure 3—Factors regulating -cell mass (24).
Table 2—Strategies to decrease/delay disease progression
Strategy Possible treatment approach
Weight loss
Eliminate glucose toxicity Early treatment early insulin
Eliminate lipotoxicity Thiazolidinediones, decrease free fatty acids
Decrease apoptosis and
increase regeneration Incretin therapies
Progression of type 2 diabetes
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function is associated with the develop-
ment of diabetes. Matveyenko et al. (31)
studied the effect of an 50% deﬁcit in
-cell mass on carbohydrate metabolism
in dogs. After partial pancreatectomy,
bothbasalandglucose-stimulatedinsulin
secretion were decreased through the
mechanism of a selective 50 and 80%
deﬁcit in insulin pulse mass, respectively.
These defects in insulin secretion were
partially offset by decreased hepatic insu-
lin clearance (P  0.05). Partial pancrea-
tectomyalsocausedan40%decreasein
insulin-stimulated glucose disposal.
Thus, an 50% deﬁcit in -cell mass can
recapitulate the alterations in glucose-
mediatedinsulinsecretionandinsulinac-
tion in humans with IFG and IGT,
supporting a mechanistic role of a deﬁcit
in-cellmassintheevolutionofIFG/IGT
and diabetes.
-Cell inﬂammation in type 2
diabetes
Inﬂammation is not in itself a disease, but
a manifestation of disease that may pre-
vent spread of infections or promote
organ regeneration. Equally, it may exac-
erbatediseasebytissuedestructiondueto
inﬂammatory mediators, reactive oxygen
species, and complement components
(32).Pancreaticisletsfromtype2diabetic
patients are known to have amyloid de-
posits, ﬁbrosis, and increased cell death
(18,32,33), associated with an inﬂamma-
tory response. Pancreatic -cells produce
increased IL-1 and other inﬂammatory
factors in response to glucotoxicity and
nutrients (32,34,35).
-Cell pancreatic function
Although the focus herein has been on
-cell function, some attention must be
paid to -cell pancreatic function in the
progressionofdiabetes.Glucoseandava-
riety of hormones and substrates work to
regulate glucagon secretion in a coordi-
nated manner, and abnormalities of
-cellsmayreﬂectimpairedglucosesens-
ing. In type 2 diabetes, relative glucagon
hypersecretion occurs at normal and ele-
vated levels of glucose and an impaired
response to hypoglycemia. The incretin
hormone GLP-1, which promotes assim-
ilation of ingested nutrients via a glucose-
dependent stimulation of insulin release,
apparently improves -cell glucose sens-
ing. Thus, GLP-1–based therapies im-
prove -cell function and may also prove
to be useful in improving glycemic con-
trol in diabetes (36).
Microvascular and macrovascular
complications
Longer survival times and development of
type 2 diabetes at younger ages increase the
risk of developing duration-dependent
complications. In UKPDS 16, 18% of pa-
tients, all of whom were presumed to be
clinically healthy, had a clinical end point
within 6 years of diagnosis.
UKPDS 35 showed highly signiﬁcant
associations between development of di-
abetes complications, including death,
across the broad range of exposure to gly-
cemia, with no evidence of a threshold.
Conversely, each 1% reduction in mean
A1Cwasassociatedwithreductioninrisk
of 21% for any end point related to dia-
betes (P  0.0001) (1).
The role of complications on disease
progression and failure has not been well
studied. A change in insulin sensitivity
and clearance is well recognized in renal
failure and clearance is well recognized.
However, the impact of these changes on
the natural history of diabetes itself needs
to be studied. Many patients with estab-
lished complications tend to be poorly
controlled, and factors such as glucose
toxicitymayplayaroleindiseaseprogres-
sion as discussed above. In addition, var-
ious cardiovascular drugs such as
diureticsand-blockersmayaffect-cell
function adversely.
CONCLUSIONS— In type 2 diabe-
tes, -cells fail to adapt to impaired glu-
cose tolerance. This failure appears to be
related to a reduction in insulin secretion
per islet as well as a reduction in the total
numberofislets.Progressivelossof-cell
function and, to a lesser extent, reduced
-cell mass lead to worsening glycemic
control and development of complica-
tions. Although they lower glucose, cur-
rent therapies do not completely abolish
this progressive loss of -cell function,
andtheiruseisalsoassociatedwithhypo-
glycemiaandweightgain(Table2).Thus,
the need for additional glucose-lowering
therapiesthatcanhalt-celldeterioration
without contributing to weight gain
continues.
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